|
注册号: Registration number: |
ChiCTR2600118323 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-04 10:50:33 |
|
注册时间: Date of Registration: |
2026-02-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
双靶点成对关联刺激促进脑卒中严重偏瘫恢复的多模态fMRI脑网络作用机制研究 |
|
Public title: |
Study on the Multimodal fMRI Brain Network Mechanism of Dual-Target Cortico-cortical Paired Associated Stimulation to Promote the Recovery of Severe Hemiplegia in Stroke Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
双靶点成对关联刺激促进脑卒中严重偏瘫恢复的多模态fMRI脑网络作用机制研究 |
|
Scientific title: |
Study on the Multimodal fMRI Brain Network Mechanism of Dual-Target Cortico-cortical Paired Associated Stimulation to Promote the Recovery of Severe Hemiplegia in Stroke Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙莉敏 |
研究负责人: |
孙莉敏 |
|
Applicant: |
Limin Sun |
Study leader: |
Limin Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 136 1168 9182 |
研究负责人电话:
Study leader's |
+86 136 1168 9182 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tracy611@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
tracy611@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福州市长乐区华山路999号 |
研究负责人通讯地址: |
福州市长乐区华山路999号 |
|
Applicant address: |
No. 999, Huashan Road, Changle District, Fuzhou City, China |
Study leader's address: |
No. 999, Huashan Road, Changle District, Fuzhou City, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
国家区域医疗中心,华山医院福建医院,福建医科大学附属第一医院滨海院区 |
||
|
Applicant's institution: |
National Regional Medical Center, Huashan Hospital, Fujian Campus, The First Affiliated Hospital of Fujian Medical University, Binhai Campus, Fuzhou |
||
|
研究负责人所在单位: |
福建医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Fujian Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
闽医大附一伦理医研[2025]812] |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建医科大学附属第一医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Affiliated Hospital of Fujian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-15 00:00:00 | ||
|
伦理委员会联系人: |
张秀秀 |
||
|
Contact Name of the ethic committee: |
Xiuxiu Zhang |
||
|
伦理委员会联系地址: |
福建省福州市茶中路20号 |
||
|
Contact Address of the ethic committee: |
No. 20, Chazhong Road, Fuzhou City, Fujian Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8798 1028 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Fujian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福州市长乐区华山路999号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 999, Huashan Road, Changle District, Fuzhou City, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建省科技创新联合资金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Joint Foundation for Scientific and Technological Innovation of Fujian Province |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本课题拟对严重偏瘫患者进行cPMd-iM1 PAS、iM1高频、cPMd高频刺激三组疗效比较及多模态fMRI研究,探讨cPMd-iM1 PAS促进严重偏瘫恢复的脑网络作用机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to compare the therapeutic effects of three groups of stimulation methods on severe hemiplegia patients: cPMd-iM1 PAS, iM1 high-frequency, and cPMd high-frequency stimulation, and conduct a multimodal fMRI study to explore the brain network mechanism underlying the promotion of severe hemiplegia recovery by cPMd-iM1 PAS. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 严重注意力障碍; 2. 严重言语、听觉、视觉、感觉、智力、精神或认知障碍; 3. 严重痉挛或疼痛; 4. 骨关节肌肉疾患、其他严重神经系统疾病、恶性肿瘤和严重心肺肝肾损害等; 5. 外地无法随访; 6.TMS禁忌证如体内有金属植入物、磁片或心脏起搏器等; 7. 酒精或药物成瘾等; 8, 癫痫 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe attention impairment; 2, Severe speech, hearing, visual, sensory, intellectual, mental, or cognitive impairments; 3. Severe spasticity or pain; 4. Bone and joint muscle diseases, other severe neurological disorders, malignant tumors, and severe damage to the heart, lungs, liver, or kidneys, etc; 5. From other cities and unable to be followed up; 6. TMS contraindications such as metal implants, magnetic plates, or cardiac pacemakers in the local body 7. Alcohol or drug addiction; 8. Epilepsy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-01 00:00:00至 To 2028-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-02-15 00:00:00 至 To 2028-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由康复科指定医生按照随机数字表对患者进行随机分组,分为三组,分别为cPMd-iM1 PAS组、iM1高频组(简称iM1组)、cPMd高频组(简称cPMd组)。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
60 stroke patients will be recruited and randomly alloccated to either the cPMd-iM1 PAS group, iM1 high frequency group or cPMd high frequency group according to the random number table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
产生随机序列的医师不参与病人入组、评估和治疗。 |
|
Blinding: |
The random sequences will be generated by the person who will not involved in the process of inclusion, treatment and evaluation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由专人负责CRF表的录入及电子数据系统的录入,保证数据真实可靠 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and electronic data capture will be managed by specific person in this research programe. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |